

FLU VACCINATION IS A GREAT TIME FOR A SHINGLES CONVERSATION



Not an actual doctor or patient.

When giving a flu vaccine to patients 50 years and older, don't miss the opportunity to discuss SHINGRIX.^{1*,†}

99.5% of people ≥50 years old are at risk for developing shingles²

1 out of 3 people will develop shingles in their lifetime²

- There are a lot of things your patients can't prevent as they age. But they can do something about shingles¹
- **In those 50 years and older, only SHINGRIX delivered >90% efficacy regardless of age^{1*}**

This flu season, ask your patients 50 years and older if they've been vaccinated against shingles

- If they haven't, discuss SHINGRIX
- SHINGRIX is indicated for prevention of shingles in adults aged 50 years and older¹

Remind patients that shingles vaccination can help them be proactive about their health

- SHINGRIX is a 2-dose series. Tell your patients it is important to receive both doses. Encourage them to schedule their second dose for anytime between 2 and 6 months after their first dose¹
- Inform patients that they may experience adverse reactions after receiving SHINGRIX. In clinical trials, the most common adverse reactions observed were pain, redness, and swelling at the injection site, myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms¹

If you don't stock SHINGRIX, consider referring your patients to their pharmacy.

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

*In an open-label clinical study, subjects 50 years and older received 1 dose each of SHINGRIX and FLUARIX QUADRIVALENT (Influenza Vaccine) (QIV) at Month 0 and 1 dose of SHINGRIX at Month 2 (n=413), or 1 dose of QIV at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n=415). There was no evidence for interference in the immune response to any of the antigens contained in SHINGRIX or the coadministered vaccine.¹

†SHINGRIX has not been studied with other influenza vaccines, including those that have an adjuvant component.

‡Data from the phase 3 ZOE-50 (≥50 years of age) trial and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials in subjects who received 2 doses of SHINGRIX (N=7344 and 8250, respectively) or placebo (N=7415 and 8346, respectively) and did not develop a confirmed case of herpes zoster within 1 month after the second dose.¹

Please see additional Important Safety Information for SHINGRIX on the next page and accompanying full Prescribing Information, also available at SHINGRIXHCP.com.



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)

Important Safety Information (cont'd)

- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
- Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
- SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

References: 1. Prescribing Information for SHINGRIX. 2. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*. 2008;57 (RR-5):1-30.

Please see additional Important Safety Information for SHINGRIX on the previous page and accompanying full Prescribing Information, also available at SHINGRIXHCP.com.

Trademarks are owned by or licensed to the GSK group of companies.



©2021 GSK or licensor.
SGXLBND210019 May 2021
Produced in USA. 0002-0012-99



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)